Travere Therapeutics Inc’s recent filing unveils that its SVP, CHIEF ACCOUNTING OFFICER Calvin Sandra unloaded Company’s shares for reported $0.26 million on Dec 26 ’24. In the deal valued at $17.22 per share,15,000 shares were sold. As a result of this transaction, Calvin Sandra now holds 54,927 shares worth roughly $0.95 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, SANDRA CALVIN bought 15,000 shares, generating $258,278 in total proceeds.
Before that, Calvin Sandra sold 12,090 shares. Travere Therapeutics Inc shares valued at $221,258 were divested by the SVP, CHIEF ACCOUNTING OFFICER at a price of $18.30 per share. As a result of the transaction, Calvin Sandra now holds 54,927 shares, worth roughly $0.95 million.
Wells Fargo upgraded its Travere Therapeutics Inc [TVTX] rating to an Overweight from a an Equal weight in a research note published on October 21, 2024; the price target was increased to $27 from $9. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in mid October with a ‘”a Sector outperform”‘ rating. Guggenheim also remained covering TVTX and has increased its forecast on September 09, 2024 with a “Buy” recommendation from previously “Neutral” rating. Guggenheim revised its rating on March 27, 2024. It rated TVTX as “a Neutral” which previously was an “a Buy”.
Price Performance Review of TVTX
On Friday, Travere Therapeutics Inc [NASDAQ:TVTX] saw its stock fall -2.81% to $17.28. Over the last five days, the stock has lost -0.69%. Travere Therapeutics Inc shares have risen nearly 92.21% since the year began. Nevertheless, the stocks have risen 81.89% over the past one year. While a 52-week high of $20.33 was reached on 11/11/24, a 52-week low of $5.12 was recorded on 04/25/24. SMA at 50 days reached $18.11, while 200 days put it at $11.36.
Levels Of Support And Resistance For TVTX Stock
The 24-hour chart illustrates a support level at 17.02, which if violated will result in even more drops to 16.75. On the upside, there is a resistance level at 17.63. A further resistance level may holdings at 17.98. The Relative Strength Index (RSI) on the 14-day chart is 43.94, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.24, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 73.51%. Stochastics %K at 26.88% indicates the stock is a holding.
How much short interest is there in Travere Therapeutics Inc?
A steep rise in short interest was recorded in Travere Therapeutics Inc stocks on 2024-12-13, growing by 0.43 million shares to a total of 7.41 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 6.97 million shares. There was a rise of 5.86%, which implies that there is a positive sentiment for the stock.
